DHTKD1 and infection: As shown in Figure 4E, when the injections were performed intratumorally, infection with Ad-CMV-E1a, Ad-hTERT-E1a, Ad-CMV-E1a-HN or Ad-hTERT-E1a-HN significantly improved the mean survival time, while the saline-treated and Ad-mock-, Ad-CMV-HN- and Ad-hTERT-HN-infected groups had lower mean survival times of 48.5 days, 43.5 days, 59.5 days and 55.5 days, respectively.